Josh Groman is currently head of underwriting for MidCap’s Life Science and Asset Based Lending groups.  Prior to joining MidCap, Dr. Groman was head of underwriting for life science transactions at Merrill Lynch Capital Healthcare Finance. From 2004 to 2007, he served as an Engagement Manager in the life sciences consulting practice at Leerink Swann & Company where he advised biotech, pharmaceutical and device manufacturers on product strategy, business development and M&A due diligence.
 
Dr. Groman holds a Ph.D. in Human Genetics and Molecular Biology from the Johns Hopkins School of Medicine and has published 11 research articles in leading scientific and medical journals. He also holds a B.S. from the State University of New York/Syracuse University and an M.S. in Biology from Vanderbilt University.